[go: up one dir, main page]

PE20121131A1 - Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina - Google Patents

Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina

Info

Publication number
PE20121131A1
PE20121131A1 PE2011002177A PE2011002177A PE20121131A1 PE 20121131 A1 PE20121131 A1 PE 20121131A1 PE 2011002177 A PE2011002177 A PE 2011002177A PE 2011002177 A PE2011002177 A PE 2011002177A PE 20121131 A1 PE20121131 A1 PE 20121131A1
Authority
PE
Peru
Prior art keywords
irbesartan
monocapa
amlodipine besylate
pharmaceutical composition
solid oral
Prior art date
Application number
PE2011002177A
Other languages
English (en)
Inventor
Praveen Khullar
Vinay Kolhe
Amol Kulkarni
Shirishbay Patel
Yashwant Phadke
D Saravanan
Mansing Shingte
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121131(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20121131A1 publication Critical patent/PE20121131A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION DE DOSIS FIJA FARMACEUTICA, ORAL, SOLIDA, ESTABLE QUE COMPRENDE: A) IRBESARTAN EN FORMA DE GRANULOS RECUBIERTOS EN 20-70% EN PESO DE LA COMPOSICION TOTAL; B) BESILATO DE AMLODIPINA EN 1-20% EN PESO DE LA COMPOSICION TOTAL Y C) EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES TALES COMO DILUYENTE, DISGREGANTE, ANTIADHERENTE, AGLUTINANTE, LUBRICANTE, ENTRE OTROS.DICHA COMPOSICION ESTA EXCENTA DE LACTOSA Y PUEDE SER EL TRATAMIENTO DE SEGUNDA LINEA PARA PACIENTES HIPERTENSOS NO CONTROLADOS SUFICIENTEMENTE USANDO AMLODIPINA COMO MONOTERAPIA DE BLOQUEANTES DE LOS CANALES DE CALCIO (CCB) O IRBESARTAN COMO ANTAGONISTA DE LOS RECEPTORES DE LA ANGIOTENSINA II (ARB)
PE2011002177A 2009-06-30 2009-09-17 Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina PE20121131A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1341DE2009 2009-06-30

Publications (1)

Publication Number Publication Date
PE20121131A1 true PE20121131A1 (es) 2012-09-04

Family

ID=41460800

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002177A PE20121131A1 (es) 2009-06-30 2009-09-17 Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina

Country Status (39)

Country Link
US (1) US9173848B2 (es)
EP (1) EP2448561B1 (es)
JP (1) JP5763063B2 (es)
KR (1) KR101667081B1 (es)
CN (2) CN106176745A (es)
AR (1) AR077284A1 (es)
AU (1) AU2009349125B2 (es)
BR (1) BRPI0925315B8 (es)
CA (1) CA2766884C (es)
CL (1) CL2011003371A1 (es)
CO (1) CO6480972A2 (es)
CR (1) CR20110704A (es)
CY (1) CY1114933T1 (es)
DK (1) DK2448561T3 (es)
DO (1) DOP2011000406A (es)
EA (1) EA021317B1 (es)
EC (1) ECSP11011559A (es)
ES (1) ES2435240T3 (es)
GT (1) GT201100337A (es)
HR (1) HRP20131088T1 (es)
IL (1) IL217229A (es)
MA (1) MA33463B1 (es)
MX (1) MX2011014005A (es)
MY (1) MY152951A (es)
NI (1) NI201100227A (es)
NZ (1) NZ597317A (es)
PE (1) PE20121131A1 (es)
PL (1) PL2448561T3 (es)
PT (1) PT2448561E (es)
RS (1) RS53087B (es)
SG (1) SG177426A1 (es)
SI (1) SI2448561T1 (es)
SM (1) SMT201400011B (es)
TN (1) TN2011000651A1 (es)
TW (1) TWI476191B (es)
UA (1) UA103688C2 (es)
UY (1) UY32749A (es)
WO (1) WO2011001202A1 (es)
ZA (1) ZA201109541B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
KR20150078215A (ko) * 2013-12-30 2015-07-08 (주) 드림파마 에프로사탄 및 암로디핀을 포함하는 복합제제 및 이의 제조방법
CN104758283A (zh) * 2014-01-02 2015-07-08 江苏吉贝尔药业有限公司 一种抗高血压制剂
CN104000821B (zh) * 2014-06-02 2020-06-19 浙江华海药业股份有限公司 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法
EP3244880A1 (en) * 2015-01-12 2017-11-22 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi A stable bilayer pharmaceutical tablet compositions comprising fixed dose of irbesartan and amlodipine
JP6737060B2 (ja) * 2015-09-11 2020-08-05 ニプロ株式会社 イルベサルタンを含有する医薬組成物の製造方法
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CA3077768A1 (en) * 2017-10-13 2019-04-18 Unichem Laboratories Ltd Pharmaceutical compositions of apremilast
CN108578404B (zh) * 2018-04-28 2020-04-28 广州白云山天心制药股份有限公司 一种含厄贝沙坦和氨氯地平的药用组合物及其制备方法
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης
CN118526494B (zh) * 2023-02-22 2025-02-07 北京阳光诺和药物研究股份有限公司 一种用于治疗高血压的药物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
KR101137084B1 (ko) * 2003-10-10 2012-04-24 애보트 프러덕츠 게엠베하 셀렉티브 ⅰ１ 이미다졸린 수용체 작용제 및 엔지오텐신 ⅱ수용체 차단제를 포함하는 약학적 조성물
US20050187262A1 (en) 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
BE1015867A3 (fr) 2004-01-22 2005-10-04 Sonaca Sa Ensemble de bord d'attaque d'un element de voilure d'aeronef et element de voilure equipee d'au moins un tel ensemble.
US20050250838A1 (en) * 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
US20080095841A1 (en) * 2004-10-06 2008-04-24 Eisai R&D Management Co., Ltd. Pharmaceutical Composition, Method for Producing the Same, and Method for Stabilizing Dihydropyridine Compound in the Pharmaceutical Composition
HRP20140212T1 (hr) * 2004-11-05 2014-04-11 Boehringer Ingelheim International Gmbh Dvoslojna tableta koja sadrži telmisartan i amlodipin
KR101384841B1 (ko) * 2005-06-27 2014-04-15 다이이찌 산쿄 가부시키가이샤 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를함유한 약학 제제
TWI388345B (zh) * 2005-06-27 2013-03-11 Sankyo Co 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
TWI402083B (zh) * 2006-12-26 2013-07-21 Daiichi Sankyo Co Ltd 固形製劑及其安定化方法

Also Published As

Publication number Publication date
UY32749A (es) 2011-01-31
MX2011014005A (es) 2012-04-30
MY152951A (en) 2014-12-15
CA2766884A1 (en) 2011-01-06
BRPI0925315B1 (pt) 2019-10-08
PL2448561T3 (pl) 2014-01-31
DOP2011000406A (es) 2012-04-15
US20120171288A1 (en) 2012-07-05
SMT201400011B (it) 2014-03-07
CN102573804A (zh) 2012-07-11
HK1169309A1 (en) 2013-01-25
EA201270087A1 (ru) 2012-07-30
WO2011001202A1 (en) 2011-01-06
AR077284A1 (es) 2011-08-17
MA33463B1 (fr) 2012-07-03
CR20110704A (es) 2012-06-15
JP2012532118A (ja) 2012-12-13
ECSP11011559A (es) 2012-01-31
ZA201109541B (en) 2013-03-27
KR101667081B1 (ko) 2016-10-17
EP2448561B1 (en) 2013-08-14
CA2766884C (en) 2016-08-23
CY1114933T1 (el) 2016-12-14
GT201100337A (es) 2014-05-20
SG177426A1 (en) 2012-02-28
TWI476191B (zh) 2015-03-11
ES2435240T3 (es) 2013-12-17
DK2448561T3 (da) 2013-11-25
EA021317B1 (ru) 2015-05-29
RS53087B (sr) 2014-06-30
AU2009349125B2 (en) 2016-05-19
KR20120102579A (ko) 2012-09-18
TW201111368A (en) 2011-04-01
NZ597317A (en) 2014-05-30
IL217229A (en) 2016-10-31
JP5763063B2 (ja) 2015-08-12
CL2011003371A1 (es) 2012-07-27
CN106176745A (zh) 2016-12-07
TN2011000651A1 (en) 2013-05-24
UA103688C2 (uk) 2013-11-11
AU2009349125A1 (en) 2012-01-19
SI2448561T1 (sl) 2013-12-31
IL217229A0 (en) 2012-07-31
NI201100227A (es) 2012-03-28
HRP20131088T1 (hr) 2013-12-20
EP2448561A1 (en) 2012-05-09
PT2448561E (pt) 2013-11-21
US9173848B2 (en) 2015-11-03
BRPI0925315B8 (pt) 2021-05-25
CO6480972A2 (es) 2012-07-16

Similar Documents

Publication Publication Date Title
PE20121131A1 (es) Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina
PE20141072A1 (es) Composiciones farmaceuticas de accion doble basadas en el bloqueo de los receptores de angiotensina y la inhibicion de la endopeptidasa neutral
UY32819A (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2
CR11709A (es) Preparacion solida de desintegracion oral
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
SV2011003905A (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o un diuretico
PE20100050A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona
PH12012502082A1 (en) Combination of active loaded granules with additional actives
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
PH12014502331A1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
NI201300106A (es) Composición farmacéutica antihipertensiva
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2015013328A (es) Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
UA115257C2 (uk) Фармацевтична композиція у формі твердої суміші, що містить кандесартану цилексетил та амлодипін
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
EA201390603A1 (ru) Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин
PE20140699A1 (es) Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma
ATE474558T1 (de) Pharmazeutische formulierungen mit irbesartan
MX358211B (es) Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
PE20090675A1 (es) Composicion farmaceutica que contie levosimendan y un antagonista receptor de angiotensina ii o un inhibidor eca
BR112013000870A2 (pt) forma de dosagem farmacêutica oral em comprimidos
CL2013001978A1 (es) Compuestos biciclicos o oxabiciclicos nitrogenados, antagonistas no competitivos moduladores de receptores nicotinicos; composicion farmaceutica que los comprende; uso de los compuestos para el tratamiento o la prevencion de hipertension, adiccion a la nicotina, depresion o ansiedad, detrioros cognitivos, inflamacion.
RU2012157622A (ru) Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed